{"id":63035,"date":"2026-04-13T20:45:22","date_gmt":"2026-04-13T12:45:22","guid":{"rendered":"https:\/\/flcube.com\/?p=63035"},"modified":"2026-04-13T20:45:23","modified_gmt":"2026-04-13T12:45:23","slug":"henlius-biotech-doses-first-patient-in-phase-i-trial-for-hlx319-a-biosimilar-to-roches-phesgo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63035","title":{"rendered":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#8217;s Phesgo"},"content":{"rendered":"\n<p><strong>Shanghai Henlius Biotech, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) has announced the dosing of the first subject in a <strong>Phase I clinical trial<\/strong> in China for <strong>HLX319<\/strong>, its proposed biosimilar to <strong>Roche\u2019s Phesgo<\/strong> (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of <strong>HER2-positive breast cancer<\/strong>, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, <strong>HLXTE-HAase02<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Randomized, double-blind, parallel-controlled, single-dose<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Healthy Chinese male subjects<\/td><\/tr><tr><td><strong>Arms<\/strong><\/td><td>1:1 randomization to HLX319 or reference Phesgo<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Single subcutaneous injection in the thigh (~5 minutes)<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>PK parameters: Cmax, AUC<sub>0-\u221e<\/sub><\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Additional PK, safety, tolerability, immunogenicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-differentiation\">Product Profile &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Indications:<\/strong> Adjuvant\/neoadjuvant treatment of HER2-positive early or locally advanced breast cancer; treatment of metastatic breast cancer.<\/li>\n\n\n\n<li><strong>Composition:<\/strong> Combines the active ingredients <strong>trastuzumab<\/strong> and <strong>pertuzumab<\/strong> with <strong>HLXTE-HAase02<\/strong>, a novel recombinant human hyaluronidase independently developed by Henlius to facilitate subcutaneous delivery.<\/li>\n\n\n\n<li><strong>Reference Product:<\/strong> Roche\u2019s <strong>Phesgo<\/strong>, which has demonstrated significant advantages over intravenous administration, including a much shorter administration time (minutes vs. hours).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biosimilars Leadership:<\/strong> This trial marks a critical step in Henlius\u2019s strategy to become a leader in complex oncology biosimilars, targeting one of Roche\u2019s most successful and clinically important combination products.<\/li>\n\n\n\n<li><strong>Subcutaneous Advantage:<\/strong> By replicating the subcutaneous format, HLX319 aims to offer the same patient-centric benefits as Phesgo\u2014dramatically reduced clinic time and improved convenience\u2014potentially at a lower cost.<\/li>\n\n\n\n<li><strong>Vertical Integration:<\/strong> The use of Henlius\u2019s own <strong>HLXTE-HAase02<\/strong> hyaluronidase showcases the company\u2019s commitment to controlling its entire value chain, from active pharmaceutical ingredients to key excipients, ensuring supply security and quality.<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> A successful biosimilar launch in China would provide more affordable access to this standard-of-care dual HER2 blockade therapy, addressing a major unmet need in a large patient population.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Value Target:<\/strong> Phesgo represents a multi-billion dollar global franchise for Roche. Biosimilars to this product are among the most sought-after in the industry due to their high clinical and commercial value.<\/li>\n\n\n\n<li><strong>Chinese Innovation:<\/strong> Henlius\u2019s development of its own hyaluronidase underscores the growing sophistication of Chinese biopharma firms in tackling complex formulation challenges associated with advanced biologics.<\/li>\n\n\n\n<li><strong>Path Forward:<\/strong> The Phase I PK study is the foundational step to demonstrate biosimilarity. Positive results will pave the way for confirmatory Phase III trials in the target patient population.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief reports on the initiation of a Phase I clinical trial. The development of HLX319 is subject to the risks inherent in clinical drug development, including the possibility of failure to demonstrate biosimilarity or an acceptable safety profile. There can be no assurance of regulatory approval.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000425_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026041000425_c.\"><\/object><a id=\"wp-block-file--media-c5e1d8f8-eeab-4028-83a9-5c3fdb08e6f9\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000425_c.pdf\">2026041000425_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026041000425_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c5e1d8f8-eeab-4028-83a9-5c3fdb08e6f9\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[43,62,270,862,163],"class_list":["post-63035","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biosimilars","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696","tag-roche"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#039;s Phesgo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63035\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#039;s Phesgo\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63035\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T12:45:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-13T12:45:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#8217;s Phesgo\",\"datePublished\":\"2026-04-13T12:45:22+00:00\",\"dateModified\":\"2026-04-13T12:45:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\",\"Roche\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63035#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63035\",\"name\":\"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche's Phesgo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T12:45:22+00:00\",\"dateModified\":\"2026-04-13T12:45:23+00:00\",\"description\":\"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\\\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63035\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63035#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#8217;s Phesgo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche's Phesgo - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63035","og_locale":"en_US","og_type":"article","og_title":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche's Phesgo","og_description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.","og_url":"https:\/\/flcube.com\/?p=63035","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T12:45:22+00:00","article_modified_time":"2026-04-13T12:45:23+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63035#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63035"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#8217;s Phesgo","datePublished":"2026-04-13T12:45:22+00:00","dateModified":"2026-04-13T12:45:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63035"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696","Roche"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63035#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63035","url":"https:\/\/flcube.com\/?p=63035","name":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche's Phesgo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T12:45:22+00:00","dateModified":"2026-04-13T12:45:23+00:00","description":"Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in a Phase I clinical trial in China for HLX319, its proposed biosimilar to Roche\u2019s Phesgo (trastuzumab\/pertuzumab). HLX319 is a subcutaneous injection for the treatment of HER2-positive breast cancer, combining trastuzumab and pertuzumab with Henlius\u2019s proprietary recombinant human hyaluronidase, HLXTE-HAase02.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63035#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63035"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63035#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche&#8217;s Phesgo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63035"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63035\/revisions"}],"predecessor-version":[{"id":63037,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63035\/revisions\/63037"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}